{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:56:57Z","timestamp":1793973417122,"version":"4.8.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000656","name":"Menzies Centre for Australian Studies, King's College London, University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000656","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jhep.2019.10.021","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T12:02:10Z","timestamp":1579089730000},"page":"320-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":260,"title":["Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0782-8647","authenticated-orcid":false,"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"El-Khoueiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-0621","authenticated-orcid":false,"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.10.021_b0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0010","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.021_b0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4004","article-title":"Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)","volume":"37","author":"Finn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.029","article-title":"LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2017.09.007","article-title":"Targets for immunotherapy of liver cancer","volume":"68","author":"Greten","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2019.10.021_b0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jhep.2019.10.021_b0050","doi-asserted-by":"crossref","first-page":"S664","DOI":"10.1016\/S0959-8049(16)31822-6","article-title":"Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-na\u00efve patients with advanced melanoma (MEL) (CheckMate 067)","volume":"51","author":"Larkin","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0055","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0060","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.jhep.2019.10.021_b0065","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.3748\/wjg.15.2960","article-title":"Systemic abnormalities in liver disease","volume":"15","author":"Minemura","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0070","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0080","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0090","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.327","article-title":"Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status","volume":"37","author":"Kudo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0105","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017."},{"key":"10.1016\/j.jhep.2019.10.021_b0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0115","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2019.10.021_b0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4073","article-title":"Phase I\/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses","volume":"35","author":"Kelley","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0973-6883(11)60235-1","article-title":"Cutaneous manifestations of common liver diseases","volume":"1","author":"Dogra","year":"2011","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0140","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhep.2019.10.021_b0145","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.021_b0150","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"10.1016\/j.jhep.2019.10.021_b0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2019.10.021_b0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","article-title":"Ipilimumab-induced perforating colitis","volume":"47","author":"Mitchell","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000444436","article-title":"Changes of intestinal functions in liver cirrhosis","volume":"1","author":"Fukui","year":"2016","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.jhep.2019.10.021_b0170","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10620-007-0065-1","article-title":"A systematic review of diagnostic tests for small intestinal bacterial overgrowth","volume":"53","author":"Khoshini","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2019.10.021_b0175","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2001.04668.x","article-title":"Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis","volume":"96","author":"Bauer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0180","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2036.2009.03994.x","article-title":"Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease","volume":"29","author":"Pande","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.10.021_b0185","first-page":"828","article-title":"Abnormalities in proximal small bowel motility in patients with cirrhosis","volume":"17","author":"Chesta","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/00365528809103971","article-title":"Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhea","volume":"23","author":"Dooley","year":"1988","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0195","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/hep.510290630","article-title":"Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study","volume":"29","author":"Chaudhry","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF01540166","article-title":"Diarrhea as a presenting symptom of hepatocellular carcinoma","volume":"35","author":"Bruix","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2019.10.021_b0205","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/1097-0142(19810601)47:11<2746::AID-CNCR2820471134>3.0.CO;2-K","article-title":"Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong","volume":"47","author":"Lai","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archsurg.1986.01400070119025","article-title":"Hepatocellular carcinoma presenting with intractable diarrhea","volume":"121","author":"Steiner","year":"1986","journal-title":"Arch Surg"},{"key":"10.1016\/j.jhep.2019.10.021_b0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archsurg.1988.01400250134033","article-title":"Hepatocellular carcinoma and the watery diarrhea syndrome","volume":"123","author":"Solinas","year":"1988","journal-title":"Arch Surg"},{"key":"10.1016\/j.jhep.2019.10.021_b0220","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(16)00097-0","article-title":"Chronic pancreatitis","volume":"387","author":"Majumder","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.021_b0225","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.pan.2017.07.194","article-title":"Analysis of lifestyle factors in patients with concomitant chronic pancreatitis and liver cirrhosis","volume":"17","author":"Aghdassi","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0240","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"JCO1900320","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0250","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0255","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009431","article-title":"Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: a case report","volume":"96","author":"Wu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2019.10.021_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.10.021_b0265","doi-asserted-by":"crossref","unstructured":"Yau T, Kang YK, TY K, El-Khoueiry AB, A S, Sangro B, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 2019;37:abstr 4012.","DOI":"10.1200\/JCO.2019.37.15_suppl.4012"},{"key":"10.1016\/j.jhep.2019.10.021_b0270","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0275","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2019.10.021_b0280","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1172\/JCI115590","article-title":"Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion","volume":"89","author":"Tsai","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2019.10.021_b0285","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.021_b0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0295","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0300","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0000000000000081","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab","volume":"38","author":"Uslu","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.jhep.2019.10.021_b0305","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0310","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jhep.2019.10.021_b0320","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0325","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1183\/09059180.00007211","article-title":"Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview","volume":"21","author":"Porres-Aguilar","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jhep.2019.10.021_b0330","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1056\/NEJMra0707185","article-title":"Hepatopulmonary syndrome\u2013a liver-induced lung vascular disorder","volume":"358","author":"Rodr\u00edguez-Roisin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2006.12.003","article-title":"Utility of pulse oximetry screening for hepatopulmonary syndrome","volume":"5","author":"Arguedas","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0340","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.20358","article-title":"Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome","volume":"40","author":"G\u00f3mez","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0345","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clinre.2014.12.011","article-title":"Porto-pulmonary hypertension: a comprehensive review","volume":"39","author":"Liberal","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0350","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jhep.2019.10.021_b0355","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","article-title":"Expert opinion on thyroid complications in immunotherapy","volume":"79","author":"Illouz","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.jhep.2019.10.021_b0360","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jhep.2019.10.021_b0365","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2019.10.021_b0370","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI108134","article-title":"Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis","volume":"56","author":"Nomura","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2019.10.021_b0375","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","article-title":"Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis","volume":"50","author":"Guo","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2019.10.021_b0380","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1440-1746.1995.tb01106.x","article-title":"Clinical associations between thyroid and liver diseases","volume":"10","author":"Huang","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0385","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.jhep.2019.10.021_b0390","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jhep.2019.10.021_b0395","first-page":"495","article-title":"Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis","volume":"15","author":"Zietz","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0400","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.4254\/wjh.v7.i8.1112","article-title":"Adrenal insufficiency in patients with decompensated cirrhosis","volume":"7","author":"Karagiannis","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0405","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.26535","article-title":"Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death","volume":"58","author":"Acevedo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.021_b0410","doi-asserted-by":"crossref","unstructured":"Kumar KVSH, Pawah AK, Manrai M. Occult endocrine dysfunction in patients with cirrhosis of liver. J Fam Med Prim Care n.d.;5:576\u201380. doi:10.4103\/2249-4863.197293.","DOI":"10.4103\/2249-4863.197293"},{"key":"10.1016\/j.jhep.2019.10.021_b0415","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0420","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jhep.2019.10.021_b0425","doi-asserted-by":"crossref","unstructured":"Murakami N, Motwani S, Riella L V. Renal complications of immune checkpoint blockade. Curr Probl Cancer n.d.;41:100\u201310. doi:10.1016\/j.currproblcancer.2016.12.004.","DOI":"10.1016\/j.currproblcancer.2016.12.004"},{"key":"10.1016\/j.jhep.2019.10.021_b0430","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (Programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 Inhibitors): results of a retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jhep.2019.10.021_b0435","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2019.10.021_b0440","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0445","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Gin\u00e8s","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0450","doi-asserted-by":"crossref","DOI":"10.1159\/000324652","article-title":"Treatment of hepatitis B virus-associated nephropathy","volume":"119","author":"Elewa","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jhep.2019.10.021_b0455","first-page":"434","article-title":"Hepatitis C virus and its renal manifestations: a review and update","volume":"8","author":"Latt","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jhep.2019.10.021_b0460","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0465","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jhep.2019.10.021_b0470","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jtho.2017.08.007","article-title":"Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors","volume":"12","author":"Feng","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0480","doi-asserted-by":"crossref","unstructured":"American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;61:642\u201359. doi:10.1016\/j.jhep.2014.05.042.","DOI":"10.1016\/j.jhep.2014.05.042"},{"key":"10.1016\/j.jhep.2019.10.021_b0485","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11011-008-9088-3","article-title":"Cognitive functioning in chronic acquired hepatocerebral degeneration","volume":"23","author":"Stracciari","year":"2008","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.jhep.2019.10.021_b0490","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/j.1478-3231.2009.02075.x","article-title":"Chronic hepatitis C virus infection associated with autonomic dysfunction","volume":"29","author":"Osztovits","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.10.021_b0495","first-page":"114","article-title":"Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection: anti-HCV therapy and autonomic function","volume":"11","author":"Osztovits","year":"2011","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jhep.2019.10.021_b0500","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2019.00454","article-title":"Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia","volume":"10","author":"Calvo","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2019.10.021_b0505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/imt-2017-0100","article-title":"Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab","volume":"10","author":"Jotatsu","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jhep.2019.10.021_b0510","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cgh.2009.02.021","article-title":"Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis","volume":"7","author":"Qamar","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0515","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cgh.2010.03.025","article-title":"Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial","volume":"8","author":"Seeff","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0520","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","author":"Peck-Radosavljevic","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.10.021_b0525","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.3748\/wjg.15.4653","article-title":"Spectrum of anemia associated with chronic liver disease","volume":"15","author":"Gonzalez-Casas","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0530","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0535","first-page":"2","article-title":"Anemia in cancer patients","volume":"25","author":"Ludwig","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2019.10.021_b0540","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/1097-0142(197909)44:3<1009::AID-CNCR2820440331>3.0.CO;2-J","article-title":"Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance","volume":"44","author":"Delsol","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0545","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.berh.2019.04.001","article-title":"Management of hepatitis B and C infections in rheumatologic disease","volume":"32","author":"Cheah","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0550","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1172\/JCI108022","article-title":"The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes","volume":"55","author":"Wands","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2019.10.021_b0555","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2005.038042","article-title":"Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren\u2019s syndrome","volume":"65","author":"Sene","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2019.10.021_b0560","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.10.021_b0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1024842817060","article-title":"The importance of alcohol-induced muscle disease","volume":"24","author":"Preedy","year":"2003","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.jhep.2019.10.021_b0570","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/mus.20168","article-title":"Effects of alcohol on skeletal and cardiac muscle","volume":"30","author":"Urbano-Marquez","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jhep.2019.10.021_b0575","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0580","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11936-017-0532-8","article-title":"Cardiovascular complications associated with novel cancer immunotherapies","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jhep.2019.10.021_b0585","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-018-0388-9","article-title":"Sick sinus syndrome associated with anti-programmed cell death-1","volume":"6","author":"Hsu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2019.10.021_b0590","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.3748\/wjg.v21.i41.11502","article-title":"Cirrhotic cardiomyopathy","volume":"21","author":"Ruiz-del-Arbol","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.10.021_b0595","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcard.2017.05.133","article-title":"Alcohol and incident atrial fibrillation \u2013 a systematic review and meta-analysis","volume":"246","author":"Gallagher","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jhep.2019.10.021_b0600","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0046-8177(84)80085-4","article-title":"Hepatitis B virus and myocarditis","volume":"15","author":"Ursell","year":"1984","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2019.10.021_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: a systematic review","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jhep.2019.10.021_b0610","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.021_b0615","first-page":"82","article-title":"Nivolumab in sorafenib-naive and -experienced patients with advanced hepatocellular carcinoma: survival, hepatic safety, and biomarker assessments in CheckMate-040","volume":"66","author":"Sangro","year":"2017","journal-title":"Hepatology A"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:39:01Z","timestamp":1759174741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0168827819306488"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}